Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

Study of Treatment Outcomes in People with CIDP

Recruiting
18 years or above
All
Phase N/A
200 participants needed
1 Location

Study Overview

This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual impairment, disability, or neurological deficits after at least three months of treatment with standard of care therapy. The study is expected to last two years. Enrollment is expected to continue for one year. Depending on when the participant is enrolled, a participant can be followed for between one and two years, through the end of study, approximately two years after the study starts.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Neurologist-confirmed diagnosis of CIDP found in the medical record, with the last neurologist visit prior to enrollment containing no information that suggests this diagnosis was reversed

  • Active use of at least one of the following CIDP treatments for three months or longer, with no evidence of discontinuation of this therapy as of the last neurologist visit prior to enrollment

    • immunoglobulin
    • corticosteroids, with the exception of prednisone (or equivalent) monotherapy at 10mg or less per day
    • plasma exchange
    • efgartigimod alfa
    • azathioprine
    • mycophenolate mofetil
    • cyclosporine
    • rituximab
    • methotrexate
  • Signed informed consent
  • Residual impairment, disability, or neurological deficits at enrollment, as defined by a raw I-RODS score of 44 or below

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Evidence of participation in any interventional clinical trial with an investigational drug at the time of enrollment
  • Hyperreflexia (increased reflexes) recorded in the medical record during a neurological exam the year before enrollment and after CIDP diagnosis
  • Aged under 18 at the time of enrollment

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

This study investigates chronic inflammatory demyelinating polyneuropathy (CIDP).

The study evaluates treatment outcomes for individuals with CIDP who have been on standard care for at least three months.

  • Who can participate: Adults aged 18 and older with a neurologist-confirmed diagnosis of CIDP who have been using specific CIDP treatments for three months or more.
  • Study details: Participants will be observed for treatment outcomes without any change to their current CIDP management. A placebo is not involved in this study.
  • Study timelines: The study will last 2 years.
Updated on 25 Jun 2025. Study ID: NCT06968975

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language